Non-Hodgkin LymphomaSymptoms, Doctors, Treatments, Advances & More
Learn About Non-Hodgkin Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Fred & Pamela Buffett Cancer Center - Nebraska Medical Center
Julie Vose is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. She has been practicing medicine for over 42 years. Dr. Vose is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. She is also highly rated in 34 other conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration.
Fred & Pamela Buffett Cancer Center - Nebraska Medical Center
Robert Bociek is an Oncologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 38 years. Dr. Bociek is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration.
Leo Gordon is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 53 years. Dr. Gordon is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Gordon is board certified in American Board Of Internal Medicine - Hematology (Certified).
Summary: The goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are: Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational medicinal product and will be followed for 36 months.
Summary: This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of...